Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14)
- Penault-Llorca, Frédérique
- Kwiatkowski, Fabrice
- Arnaud, Antoine
- Levy, Christelle
- Leheurteur, Marianne
- Uwer, Lionel
- Derbel, Olfa
- Le Rol, Annick
- Jacquin, Jean-Philippe
- Jouannaud, Christelle
- Quenel-Tueux, Nathalie
- Girre, Véronique
- Foa, Cyril
- Guardiola, Emmanuel
- Lortholary, Alain
- Catala, Stéphanie
- Guiu, Séverine
- Valent, Alexander
- Boinon, Diane
- Lemonnier, Jérome
- Delaloge, Suzette
DOIAbstract
International audienceGenomic tests can identify ER-positive HER2-negative localized breast cancer patients who may not benefit from adjuvant chemotherapy. Such tests seem especially interesting in "intermediate" clinico-pathological risk categories. The psychological impact of the decision uncertainty in these women remains largely unexplored. We assessed the clinical and psychological impact of EndoPredict® (EpClin), a clinico-genomic test, in these patients
Add to ORKG